Opendata, web and dolomites

ESPS SIGNED

Epileptic Seizure Prediction System (ESPS) - Predicting and preventing epileptic seizures based on respiratory biofeedback & machine learning.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ESPS project word cloud

Explore the words cloud of the ESPS project. It provides you a very rough idea of what is the project "ESPS" about.

learning    stress    disorders    received    feasibility    visits    week    decades    personalize    structured    prediction    pillars    market    healthcare    therapies    saving    onset    predicting    alone    independent    hesitant    obtain    shared    disrupt    seizure    treatment    cycle    clinicians    14    life    nature    seizures    desired    pending    patterns    hospital    reduces    burden    majority    introduction    tracking    methodology    epilepsy    homecare    wearable    intensity    business    prone    risks    despite    algorithm    50m    clinical    patient    plan    changed    regulatory    cure    injuries    disrupts    detection    lives    time    introducing    personalized    entering    care    elderly    probability    intervention    literally    reducing    70    children    health    14b    alert    staggering    unpredictable    nervous    boston    calculates    shift    ibreve    worldwide    employment    people    harvard    follow    patients    drugs    hard    preventive    analyzes    caregiver    clinician    caretaking    leave    house    respiratory    sent    causes    machine    reliably    patent    antiepileptic    innovation    caused    trials    pharmacological    esps   

Project "ESPS" data sheet

The following table provides information about the project.

Coordinator
IBREVE LIMITED 

Organization address
address: GROUND FLOOR 8-9 MARINO MART FAIRVIEW
city: DUBLIN
postcode: D03 P590
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.epilepsy.ibreve.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IBREVE LIMITED IE (DUBLIN) coordinator 50˙000.00

Map

 Project objective

Epilepsy is one of the most common nervous system disorders and affects more than 50M people worldwide. The majority of new-onset cases occur in elderly and children. Currently there is no cure for epilepsy. Although antiepileptic drugs can help, one third of all patients do not respond to any pharmacological intervention. This staggering number has not changed in decades, despite over 14 new therapies entering the market. The unpredictable nature of seizures causes the largest burden for patients as it literally disrupts their lives. Patients with several seizures a week are hesitant to leave the house & find it hard to obtain employment. Reliably predicting seizures enables an independent life for the patient and at the same time reduces healthcare costs caused by clinician visits, injuries & caretaking. iBreve’s new patent-pending wearable technology analyzes respiratory patterns in real-time, enabling market applications for seizure prediction, respiratory treatment & stress management. iBreve’s technology received interest from Harvard’s Boston Children’s Hospital to be included in clinical trials for seizure detection & prediction. The ESPS machine learning algorithm calculates seizure probability & intensity and if desired an alert is sent to the patient’s caregiver. The tracking and analysis of seizures can be shared with clinicians & allows to personalize treatment. Main objective of this feasibility study is the development of a comprehensive business plan to evaluate the opportunities & risks of introducing ESPS into the homecare market. All project activities follow the Healthcare Innovation Cycle methodology & are structured around 4 development pillars - Technology, Market & Business, Clinical and Regulatory. The introduction of ESPS is prone to disrupt the epilepsy market by reducing treatment costs per patient by up to 70%. Thus, saving 14B€ in health care costs in Europe alone and creating a major shift towards preventive & personalized treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESPS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ESPS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

LTS (2020)

LEARNING TO SLEEP: INCREASING HEALTH THROUGH BETTER SLEEP

Read More